Nejm Daraxonrasib In Previously Treated Advanced Ras Mutated Pancreatic Cancer (1)

The n e w e ng l a n d j o u r na l of m e dic i n e Original Article Da­ra­xon­ras­ib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer Brian M. Wolpin, M.D., M.P.H.,1 Wungki Park, M.D.,2 Ignacio Garrido‑Laguna, M.D., Ph.D.,3 Alexander Spira,... More

The n e w e ng l a n d j o u r na l of m e dic i n e Original Article Da­ra­xon­ras­ib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer Brian M. Wolpin, M.D., M.P.H.,1 Wungki Park, M.D.,2 Ignacio Garrido‑Laguna, M.D., Ph.D.,3 Alexander Spira, M.D., Ph.D.,4 Alexander Starodub, M.D., Ph.D.,5* David Sommerhalder, M.D.,6 Salman R. Punekar, M.D.,7 Minal Barve, M.D.,8 Meredith Pelster, M.D.,9 Benjamin Herzberg, M.D.,10 Nilofer S. Azad, M.D.,11 Joel Randolph Hecht, M.D.,12 Sai Hong Ignatius Ou, M.D., Ph.D.,13 Tong Lin, Ph.D.,14 Sumit Kar, Ph.D.,14 Lin Tao, M.S.,14 Rashmi Vora, M.B., B.S.,14 Aparna Hegde, M.D.,14 Kyaw Aung, M.B., B.S., Ph.D.,15 and David S. Hong, M.D.,16 for the RMC-6236-001 Investigators†​​ A BS T R AC T BACKGROUND Author affiliations are listed at the end of Current therapies for patients with pancreatic ductal adenocarcinoma (PDAC) pro- the article. Brian M. Wolpin can be con- vide modest benefit. Activating RAS mutations occur in more than 90% of PDAC tacted at Less